Dr. Michael Morris, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Icahn School of Medicine at Mount Sinai (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 163
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: Icahn School of Medicine at Mount Sinai
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 202032
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Memorial Solid Tumor Group (234 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 163
- Services billed
- 522
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 190 | 107 |
| Established patient office or other outpatient visit, 30-39 minutes | 142 | 78 |
| New patient office or other outpatient visit, 60-74 minutes | 27 | 27 |
| Established patient office or other outpatient visit, 40-54 minutes | 15 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Nubeqa (darolutamide) | 120 |
| Prednisone Other prescribers in New York, NY | 98 |
| Xtandi (enzalutamide) | 87 |
| Abiraterone Acetate | 72 |
| Orgovyx (relugolix) | 65 |
| Erleada (apalutamide) | 22 |
| Alendronate Sodium Other prescribers in New York, NY | 16 |
| Tamsulosin Hcl Other prescribers in New York, NY | 13 |
| Zytiga (abiraterone acetate) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 36 payments worth $26,093 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $14,453 |
|---|---|
| AbbVie Inc. | $7,958 |
| GlaxoSmithKline, LLC. | $2,400 |
| Janssen Global Services, LLC | $547 |
| Amgen Inc. | $373 |
| Progenics Pharmaceuticals, Inc. | $265 |
| AstraZeneca Pharmaceuticals LP | $97.00 |
| Consulting Fee | $21,089 |
|---|---|
| Travel and Lodging | $3,797 |
| Food and Beverage | $1,207 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Oct 20, 2025 | Consulting Fee | $12,889 |
| AbbVie Inc. Dec 8, 2025 | Consulting Fee | $5,800 |
| GlaxoSmithKline, LLC. Apr 2, 2025 | Consulting Fee | $2,400 |
| Janssen Global Services, LLC Sep 22, 2025 | Travel and Lodging travel to NEW BRUNSWICK, NJ · in-kind | $533 |
| AbbVie Inc. Nov 9, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionM24-742 | $509 |
| E.r. Squibb & Sons, L.l.c. Sep 2, 2025 | Travel and Lodging travel to Boston, MA | $387 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $387 |
| AbbVie Inc. Nov 8, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionM24-742 | $281 |
| AbbVie Inc. Nov 9, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionM24-742 | $281 |
| AbbVie Inc. Nov 10, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionM24-742 | $281 |
All 19 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 8, 2025 | Consulting Fee | $5,800 |
| AbbVie Inc. Dec 8, 2025 | Travel and Lodging travel to NEW YORK, NY · in-kind | $158 |
| AbbVie Inc. Nov 10, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionM24-742 | $281 |
| AbbVie Inc. Nov 9, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionM24-742 | $509 |
| AbbVie Inc. Nov 9, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionM24-742 | $281 |
| AbbVie Inc. Nov 9, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionM24-742 | $92.28 |
| AbbVie Inc. Nov 8, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionM24-742 | $281 |
| AbbVie Inc. Nov 8, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionM24-742 | $198 |
| E.r. Squibb & Sons, L.l.c. Oct 28, 2025 | Travel and Lodging travel to BOSTON, MA | $165 |
| E.r. Squibb & Sons, L.l.c. Oct 20, 2025 | Consulting Fee | $12,889 |
| Janssen Global Services, LLC Sep 22, 2025 | Travel and Lodging travel to NEW BRUNSWICK, NJ · in-kind | $533 |
| Janssen Global Services, LLC Sep 22, 2025 | Travel and Lodging travel to NEW YORK, NY · in-kind | $5.50 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $387 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $258 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $37.74 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $19.98 |
| E.r. Squibb & Sons, L.l.c. Sep 2, 2025 | Travel and Lodging travel to Boston, MA | $387 |
| GlaxoSmithKline, LLC. Apr 2, 2025 | Consulting Fee | $2,400 |
| Amgen Inc. Jan 21, 2025 | Travel and Lodging travel to BARCELONA, Spain | $203 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 7 companies. The companies reported $4,955,296 in research payments for these studies, mostly to the institutions running them.
- Collaboration Agreement - Prostate Cancer Clinical Trials Consortium, LLC, The (PCCT)
Bayer HealthCare Pharmaceuticals Inc. - A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer
Janssen Research & Development, LLC - A phase 1, open-label, functional imaging study to assess whether CC-90011 reverses the castration resistance due to lineage switch in participants with metastatic castration-resistant prostate cancer (mCRPC) who have…
Celgene Corporation - A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Global Development - PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Re…
Novartis Pharmaceuticals Corporation - A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With …
Amgen Inc. - A phase 1, open-label, functional imaging study to assess whether CC-90011 reverses the castration resistance due to lineage switch in participants with metastatic castration-resistant prostate cancer (mCRPC) who have…
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.